Skip to content
Asahi Kasei
-
Asahi Kasei installs novel FO-MD system at Peptistar to speed up API manufacturing
The move marks an important step toward evaluating the technology for Good Manufacturing Practice (GMP)-compliant manufacturing while improving the efficiency of producing next-generation medicines.
-
Asahi Kasei Life Science licenses the Noguchi Institute ADC platform to advance precision biologic therapies
The Noguchi Institute’s newly licensed technology focuses on controlling two critical aspects of ADC design: the drug-to-antibody ratio (DAR) and the precise attachment site of the therapeutic payload.
-
Asahi Kasei completes the acquisition of Aicuris to strengthen the infectious disease portfolio
By integrating Aicuris into its global development and commercialization infrastructure, Asahi Kasei accelerates its expansion in the specialty pharmaceutical sector.